US · ROIV
Roivant Sciences Ltd.
- Sector
- Healthcare · Biotechnology
- Headquarters
- London SW1Y 4LB
- Website
- roivant.com
Price · as of 2025-03-31
$27.83
Market cap 20.71B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $29.81 | +7.11% |
| Intrinsic Value(DCF) | $7.32 | -73.7% |
| Graham-Dodd Method(GD) | $5.28 | -81.04% |
| Graham Formula(GF) | $0.61 | -97.8% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $9.96 | $31.75 | $1.00 | $0.00 | $63.64 |
| 2022 | $3.87 | $39.04 | $0.21 | $0.00 | $0.00 |
| 2023 | $10.03 | $26.56 | $0.00 | $0.00 | $0.00 |
| 2024 | $10.47 | $78.59 | $7.25 | $35.27 | $0.00 |
| 2025 | $11.23 | $29.81 | $4.71 | $5.28 | $0.61 |
AI valuation
Our deep-learning model estimates Roivant Sciences Ltd.'s (ROIV) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $29.81
- Current price
- $27.83
- AI upside
- +7.11%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$7.32
-73.7% upside
Graham-Dodd
$5.28
-81.04% upside
Graham Formula
$0.61
-97.8% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ROIV | Roivant Sciences Ltd. | $27.83 | 20.71B | +7% | -74% | -81% | -98% | -22.84 | 1.74 | 280.39 | -3.06 | — | 1.74 | 96.86% | -3453.32% | -591.96% | -6.70% | 1167.58% | -5.64% | 0.02 | — | 33.47 | 32.71 | 2.38 | -10459.00% | -1119.00% | 1010.00% | -10.36% | -5.62 | 982.26% | 0.00% | 0.00% | 15.88% | -3.35 | -3.98 | 115.63 | 20.07 |
| ASND | Ascendis Pharma A/S | $233.50 | 14.33B | -41% | +2,942% | — | — | -57.24 | -77.03 | 18.12 | -112.32 | — | -75.32 | 85.08% | -18.92% | -31.67% | 163.18% | -92.10% | -17.65% | -5.35 | -1.69 | 1.04 | 0.72 | -2.24 | -4456.00% | 9022.00% | -11418.00% | 0.35% | 0.05 | 30.69% | 0.00% | 0.00% | 0.46% | -97.73 | 293.28 | 18.49 | 2.47 |
| BBIO | BridgeBio Pharma, Inc. | $66.48 | 12.89B | -12% | +7,582% | — | — | -17.82 | -6.22 | 25.73 | -22.38 | -56.40 | -6.14 | 94.37% | -113.35% | -145.26% | 40.90% | 321.74% | -78.14% | -1.31 | -10.72 | 2.62 | 2.52 | -3.21 | 3160.00% | 12626.00% | -1431.00% | -3.46% | -1.55 | 252.72% | 0.00% | 0.00% | 0.37% | -26.46 | -33.69 | 30.00 | -4.02 |
| EXAS | Exact Sciences Corporatio… | $103.38 | 19.73B | -34% | -59% | — | — | -93.78 | 8.12 | 6.01 | 171.91 | — | -21.99 | 69.69% | -3.05% | -6.40% | -8.66% | -2.45% | -3.53% | 1.05 | -3.01 | 2.43 | 1.97 | 12.79 | -8032.00% | 1769.00% | 37860.00% | 1.83% | 0.77 | 8.83% | 0.00% | 0.00% | 3.01% | -212.55 | 59.02 | 6.49 | 2.94 |
| IONS | Ionis Pharmaceuticals, In… | $81.15 | 13.14B | -40% | -60% | — | — | -34.38 | 26.82 | 13.89 | -46.25 | — | 26.82 | 98.31% | -40.47% | -40.36% | -70.80% | -221.28% | -11.69% | 5.78 | -5.23 | 1.95 | 1.79 | -8.56 | -2171.00% | 3387.00% | -4141.00% | -2.44% | -0.18 | -185.38% | 0.00% | 0.00% | 0.00% | -34.72 | -41.44 | 14.05 | 1.95 |
| JAZZ | Jazz Pharmaceuticals plc | $190.02 | 11.7B | -5% | -56% | -94% | — | -32.61 | 2.69 | 2.72 | 104.22 | — | -5.99 | 88.21% | 5.26% | -8.35% | -8.47% | 2.26% | -3.01% | 0.25 | 1.15 | 1.86 | 0.99 | -2.87 | -16751.00% | 488.00% | -377.00% | 11.17% | 0.60 | 23.02% | 0.00% | 0.00% | 36.04% | 50.37 | 8.72 | 2.65 | 1.65 |
| MRNA | Moderna, Inc. | $53.57 | 20.93B | -39% | -52% | — | +298% | -7.28 | 2.38 | 10.57 | -6.53 | — | 2.38 | 55.35% | -158.13% | -145.16% | -28.87% | -65.47% | -21.31% | 0.22 | — | 3.29 | 3.01 | 0.27 | -2168.00% | -3923.00% | -4908.00% | -10.05% | -0.94 | -43.98% | 0.00% | 0.00% | 0.00% | -5.42 | -8.07 | 8.58 | 3.94 |
| RNA | Avidity Biosciences, Inc. | $14.75 | 2.28B | +47% | -35% | — | — | -3.00 | 1.22 | 109.48 | -0.66 | -4.17 | 1.22 | 77.87% | -3977.30% | -3650.39% | -43.98% | -9010.06% | -38.88% | 0.06 | — | 9.20 | 8.75 | 0.42 | 7197.00% | 7211.00% | 11555.00% | -32.33% | -3.33 | -8017.39% | 0.00% | 0.00% | 3.65% | -0.60 | -0.68 | 24.04 | 3.18 |
| RPRX | Royalty Pharma plc | $46.21 | 19.8B | +84% | -35% | -81% | -50% | 15.48 | 3.17 | 8.62 | 17.62 | 64.14 | 3.69 | 100.00% | 65.58% | 32.42% | 19.73% | 11.31% | 7.00% | 1.38 | 5.07 | 0.97 | 2.39 | 5.09 | 2414.00% | 506.00% | -1008.00% | 12.14% | 3.91 | 18.06% | 1.84% | 28.60% | 7.83% | 18.48 | 11.57 | 12.12 | 1.79 |
| RVMD | Revolution Medicines, Inc… | $102.02 | 19.72B | — | — | — | — | -17.08 | 11.84 | — | -16.01 | -25.80 | 12.38 | 0.00% | — | — | -58.07% | 1908.09% | -46.06% | 0.10 | -48.80 | 7.14 | 6.97 | 0.21 | 6620.00% | — | 6094.00% | -4.73% | -3.09 | 1474.57% | 0.00% | 0.00% | 0.00% | -14.76 | -19.10 | — | 13.58 |
| SMMT | Summit Therapeutics Inc. | $16.59 | 12.35B | — | — | — | — | -11.21 | 18.37 | — | -14.24 | -3.08 | 18.43 | 0.00% | — | — | -206.10% | 2928.71% | -181.94% | 0.02 | — | 9.87 | 9.77 | 0.26 | 36452.00% | — | 12749.00% | -2.67% | -4.42 | 1166.77% | 0.00% | 0.00% | 0.93% | -14.04 | -35.25 | — | 72.96 |
About Roivant Sciences Ltd.
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
- CEO
- Matthew Gline
- Employees
- 908
- Beta
- 1.23
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($7.32 ÷ $27.83) − 1 = -73.7% (DCF, example).